Outpost Bio, a company
focused on decoding complex interactions in human biology, has raised a $3.5
million pre-seed round co-led by Merantix Capital and Seedcamp, with
participation from OpenSeed VC, Defined, and several strategic family offices
and angel investors.
Human microbiology
examines how microbial communities living in and on the body metabolise drugs,
process nutrients, and influence health outcomes. Despite being one of the most
complex and data-rich areas in biology, it remains difficult for R&D teams
to translate this complexity into actionable insights. While many biological
frontier models focus primarily on components encoded in human DNA, biological
function emerges from interactions across multiple systems.
Outpost Bio aims to
address this gap by developing frontier models at the interaction layer with a
focus on human microbiology. Its Lab-in-the-Loop platform combines automated
experimentation with machine learning to create a closed feedback loop in which
models learn from experimental results and guide subsequent testing.
The approach generates
proprietary, human-derived functional data at scale, supporting pharmaceutical
partners in reducing clinical risk, designing safer formulations, and
strengthening regulatory evidence.
Beyond pharmaceuticals,
food and consumer companies can use the platform to assess how prebiotics,
botanicals, and other ingredients influence microbial communities.
The new funding will
support the further development of Outpost Bio’s experimental and modelling
platforms, enabling new approaches to the design of drugs, ingredients, and
consumer health products.